Some more good press, CxBladder is a finalist for the innovators of the year...
http://www.idealog.co.nz/blog/2013/0...lists-revealed
Printable View
Some more good press, CxBladder is a finalist for the innovators of the year...
http://www.idealog.co.nz/blog/2013/0...lists-revealed
Can anybody please tell me what's going on with CxColorectal?
http://www.pacificedge.co.nz/cxcolorectal
The website is hardly splurging information. Of interest is the last line 'It is anticipated that the test will be launched in the Australasian market by Pacific Edge by mid 2012'.
So this should have happened by now?
Disc; Like the product so starting research!
At the AGM David Darling advised that cxcolorectal was on hold awaiting cashflow. The suggestion, as I understood it, was that the development of the now four cxbladder products was a more lucrative prospect as they can all be marketed with the same sales force into the same customer base. When cxcolorectal is kicked off, it must be marketed to oncologists rather than urologists, thus a different customer base.
In addition, advice was also provided suggesting that the roll out of the cxbladder products will occur at a rate that revenues will support, the implication was that the five sales staff for cxbladder will be increasingly ramped up over time as cashflow supports toward the target of 19 as the priority.
He responded to a question in regard to concern that competitors may potentially overtake PEB whilst cxcolorectal was on hold, by saying that yes that was a concern, but cxbladder was the priority. I took from this that cxbladder is far more advanced and is already commercial thus PEB must prioritise available cashflow to it for now.
But, what a great position to be in having too many great products to progress.
Trust this assists.
Thank you all. I shall read up and undoubtedly end up with more questions than answers!
Ian Clements has yet a further update for those, like myself, who may be following his independent comparison of cxbladder and the only other, albeit dated and lower tech, competitor in the market NMP22.
What I like about this comparison is that it’s entirely independent feedback directly from the market. I think his quote below sums up succinctly what cxbladder will do for those unfortunate enough to be inflicted with bladder cancer;
“For my money (well, actually not my money, more my life), Cxbladder appears more likely to reflect my cancerousness, and more quickly too”.
http://bladdercancerfight.blogspot.c...noma-womb.html
PEB’s own extensive research and the market also now is starting to regard cxbladder as a superior product to NMP22, and of course cxbladder is more versatile and has applications well beyond NMP22’s specification.
Given that there is no other competition close to commercialisation and that the barriers to entry for this market are simply enormous, with clinical trials and regulatory approvals requiring years, it would seem that PEB are looking quite well placed to make an impact in this market ?.
Sorry about this, I only looked back at these today!
All of this information is available and researched already and in this forum.
The current incumbent is NMP22 - Alere/Matritech. There are others but none appear to be used as widely. I can't find sales figures on them but I did read a quote from the CEO in 2007 which said they had sold over a million tests. That was in 2007 and it had only really gone to market with it in 2001 (previously Matritech appeared to be failing to sell substantial numbers). They report a 50% margin, hence my use of the same figure.
PEB are direct selling to hospitals and LUGs at the moment, distributor agreements could be forthcoming, we just don't know. You can be skeptical that a hospital won't dump a tried and tested product for an unknown one only for so long - every test (and there have been 3 major ones at least), plus peer reviewed articles point to the product being superior in a number of ways, not just accuracy.
For a bit of perspective
PEB are doing user trials with 5 LUG groups in the US. Each group has approx 100 members so lets say that is 500 urologists. In order to achieve 9128 tests then each urologist will have to see 1.5 patient tests per month. If I may humbly suggest that there are probably a lot more than that presenting with haematuria on a per urologist
basis. Anything that can do the test quickly, accurately, non invasively and with less cost overall will be the one to succeed.
By the way, Schrodinger - hows the cat?
lets say 10 percent do take it on then they would have to see a patient every second day to make the 9128 tests which is in my opinion is not particularly busy. These are only the LUG groups trials not sales, I am trying to make the point that 9128 in sales seems fairly achievable if 10 percent of 5 Lug groups take cxbladder on board
Once this happens and confidence grows word of mouth will probably get a much bigger part of the group involved.
Thanks for that information Brighton Early, can you provide a link or a reference, many thanks.
The quote below is from the FY13 annual report which suggests that the user programs are about all done by this time and that PEB anticipate that they should be translating into full commercial relationships which will add to revenue within 2013.
Attachment 4830
IMO, a business model with a philanthropic aspect is always well rewarded over time. Whereas, one based solely on "how much money can we make?" per se' is fundamentally flawed and won't ever reach its full potential.
At the risk of over-whipping the horse, I think PEB is in a good space in all respects. They have the right product/s, the right attitude, the right management and the right business model to do very well indeed.
I wonder if this is where the phase " getting p--sed " came from?
Two things we need for PEB, Doctors and Patience.:)
Appears as though someone got nervous once the SP reached back to the dizzy heights of 58c.
Could've been the beginning of a new upward trend but ...